Fairness and Subgroup Performance in Clinical Prediction Models

Clinical prediction models influence screening, referral, monitoring, treatment selection, and allocation of limited healthcare resources. Their performance is often summarized as if the target population were homogeneous. A pooled C-statistic, calibration plot, or overall accuracy can look acceptable while concealing systematic differences in predictions or decisions for clinically important subgroups.

Fairness analysis does not mean selecting a single universal metric and declaring a model fair when that number is similar across groups. Clinical prediction involves base-rate differences, measurement variation, missingness, treatment access, and outcome ascertainment. Some performance criteria can be mathematically incompatible when outcome prevalence differs. A responsible evaluation therefore begins with a clear clinical question and treats fairness as a multidimensional assessment of performance, applicability, and consequences.

1. Define the fairness question before choosing a metric

The first question is not “Which fairness metric should be used?” It is “What disparity could cause harm in this clinical use case?” A diagnostic model may raise concern about unequal sensitivity for a serious condition. A prognostic model may require comparable calibration so that a predicted risk has the same meaning across groups. A triage model may require comparison of net benefit because unequal threshold decisions can determine access to specialist care.

Specify the population, prediction time, outcome horizon, action threshold, and subgroup variables before analysis. Subgroups may be defined by age, sex, race or ethnicity, geography, socioeconomic position, disability, language, insurance status, or other characteristics that are relevant to the clinical pathway and data-generating process. Use respectful, transparent terminology and explain how each variable was measured, coded, and justified.

Prespecification reduces selective reporting. If investigators examine dozens of subgroup definitions and report only the most favorable comparison, readers cannot distinguish a stable finding from a chance result. A subgroup analysis plan should also state whether the analysis is confirmatory or exploratory and how multiplicity and small subgroup sizes will be handled.

2. Separate data inequity from algorithmic performance

Observed subgroup disparities can arise from several layers of the healthcare system. The training data may underrepresent a group, predictors may be measured differently, outcome labels may reflect unequal access to diagnosis, or clinical documentation may be less complete in one setting. The model can then reproduce or amplify differences that originated before algorithm fitting.

Model evaluation should describe recruitment, inclusion criteria, missingness, follow-up, reference standards, and outcome ascertainment for every important subgroup. A lower observed event rate may reflect true risk differences, selection into care, differential testing, or incomplete follow-up. Treating the observed label as an unquestioned ground truth can make a model appear fair while preserving inequity in the measurement process.

This does not make performance metrics irrelevant. It changes how they should be interpreted. Researchers should report data limitations alongside discrimination and calibration, identify where the model is likely to be used, and distinguish statistical disparity from the clinical or social mechanism that produces it.

3. Compare subgroup discrimination without overclaiming

Discrimination describes how well the model ranks individuals with and without the outcome. Report subgroup-specific measures such as the C-statistic, area under the receiver operating characteristic curve, sensitivity, specificity, or time-dependent discrimination when appropriate. Include confidence intervals and subgroup sample sizes.

Differences in discrimination are not automatically evidence of bias. A subgroup with a narrower risk spectrum may have a lower attainable AUC even when the model is clinically useful. Conversely, similar AUC values do not establish fairness because AUC does not assess whether predicted probabilities are accurate or whether decisions are distributed equitably.

Use discrimination comparisons to identify where ranking performance differs, then examine calibration and clinical utility. Avoid converting small numerical differences into categorical claims without considering uncertainty, clinical thresholds, and the consequences of false positives and false negatives.

4. Calibration determines whether risk estimates mean the same thing

Calibration asks whether predicted risks agree with observed outcomes. Overall calibration-in-the-large can identify systematic overprediction or underprediction, while the calibration slope indicates whether predictions are too extreme or too narrow. These quantities should be reported within clinically relevant subgroups rather than only in the pooled sample.

Equal calibration is often clinically important for prognostic models. If a model predicts a 20% risk for two groups, clinicians and patients may reasonably interpret that value as comparable unless the model is explicitly intended to encode different meanings. Calibration plots with adequate smoothing, observed-to-expected summaries, and uncertainty intervals are preferable to a single calibration p-value.

Calibration can also vary across the risk range. A model may be well calibrated at low risk but overpredict high-risk patients in one group. Examine the threshold region that drives decisions, not only the average intercept or slope. If recalibration is considered, report the original subgroup performance before updating and validate the updated model independently.

5. Evaluate error rates in the context of the decision

Sensitivity and specificity are useful for diagnostic decisions, but their interpretation depends on outcome prevalence and the action attached to a threshold. Positive and negative predictive values also vary with prevalence. Metrics such as equalized odds, equal opportunity, or predictive value parity represent different policy choices; they are not interchangeable definitions of fairness.

For a clinical prediction model, error costs are rarely symmetric. A false negative may delay urgent treatment, whereas a false positive may trigger an invasive test, anxiety, or resource use. The relevant fairness question may therefore be whether harms are distributed acceptably at a fixed threshold, whether each group receives an appropriate threshold, or whether the model produces comparable net benefit under realistic care pathways.

Threshold selection should be made explicit. Report performance at the prespecified clinical threshold and, where useful, across a range of thresholds. Do not tune separate thresholds solely to make a metric equal across groups without examining the effects on workload, missed cases, overtreatment, and clinician interpretation.

6. Use decision-analytic measures to assess subgroup utility

Decision Curve Analysis evaluates net benefit across threshold probabilities by weighing true-positive gains against false-positive harms. A subgroup version can show whether using the model adds more clinical value than treat-all or treat-none strategies within each group. This is closer to a deployment question than comparing AUC alone.

Subgroup net benefit should be linked to a real action. A threshold range is meaningful only if clinicians would consider acting within that range. Researchers should explain whether the same threshold is clinically justified across groups and whether different baseline risks or resource constraints alter the decision context.

Decision curves do not solve every fairness problem. A model can have similar net benefit while exposing one group to a different distribution of false negatives, or a high net benefit can reflect a benefit function that does not capture patient priorities. Use net benefit alongside calibration, error rates, subgroup size, and qualitative assessment of implementation consequences.

7. Evidence summary table

8. A practical fairness-evaluation workflow

9. Handle small subgroups and uncertainty honestly

Small subgroups create imprecise estimates and unstable calibration plots. A wide confidence interval is not evidence that performance is equal; it is evidence that the study may not be able to distinguish plausible differences. Report the number of participants and events, use appropriate shrinkage or hierarchical methods when justified, and avoid suppressing subgroup results solely because they are inconvenient.

Interactions can be useful for testing whether predictor effects differ across groups, but they require adequate information and a prespecified interpretation. Do not rely on a non-significant interaction p-value to prove fairness. The absence of statistical evidence for difference is not evidence of equivalence.

When subgroup sizes are limited, combine quantitative results with external evidence, stakeholder input, and a clear plan for prospective monitoring. A model may be unsuitable for deployment in an underrepresented group even when available estimates look numerically acceptable.

10. Mitigation is a clinical design decision

Potential responses include improving data collection, revising outcome definitions, recalibrating probabilities, adding predictors, changing thresholds, using group-specific calibration, or deciding not to deploy the model in a setting where evidence is inadequate. Each response changes the relationship between predictions and clinical action.

Mitigation should be evaluated against the original problem. Recalibration may improve subgroup calibration but alter overall risk ranking. Group-specific thresholds may equalize one error metric while worsening another. Adding a predictor may improve performance in one group but increase measurement burden or privacy concerns. Report the trade-offs rather than presenting mitigation as a technical correction without clinical consequences.

11. AI models require subgroup monitoring after deployment

Fairness is not a one-time property established by a development dataset. Patient mix, coding, equipment, referral patterns, treatment availability, and outcome definitions may change after deployment. AI models can also respond to site-specific artifacts that are not clinically meaningful.

Predefine monitoring variables, performance thresholds, review intervals, and escalation rules. Track subgroup calibration, discrimination, missingness, threshold decisions, and outcome ascertainment over time. Include clinicians and affected patient communities in discussions about what constitutes unacceptable performance and what action should follow a detected disparity.

12. Common reporting errors

Common errors include reporting overall AUC without subgroup results, treating equal accuracy as proof of fairness, omitting subgroup event rates, using sensitive variables without explaining their measurement, comparing metrics without uncertainty, and claiming that a model is fair because no disparity reached statistical significance.

Another error is using a fairness metric disconnected from the clinical action. A mathematically balanced error rate may not improve patient outcomes, while a model with unequal sensitivity may still be appropriate if the threshold and care pathway are designed to prevent unacceptable harm. A credible report states which fairness dimension was prioritized and why.

Conclusion

Fairness evaluation in clinical prediction models is a structured investigation of subgroup performance and clinical consequences, not a single pass-fail statistic. Define the intended decision, describe how data and outcomes were generated, report discrimination and calibration within meaningful subgroups, examine error rates and thresholds, and compare clinical utility where appropriate. TRIPOD+AI and PROBAST+AI support transparent reporting and appraisal, while subgroup net benefit connects statistical differences to patient-level decisions. A model should be considered ready for clinical use only when its performance, limitations, and monitoring plan are understood across the populations it is intended to serve.